Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India flag India · Delayed Price · Currency is INR
1,704.60
+9.50 (0.56%)
At close: Feb 9, 2026

Revenue

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
India Formulations Revenue
186.67B169.23B148.89B
India Formulations Revenue Growth
10.31%13.66%9.46%
US Formulations Revenue
166.45B162.40B153.49B
US Formulations Revenue Growth
2.49%5.80%13.40%
Emerging Market Revenue
106.46B94.16B86.19B
Emerging Market Revenue Growth
13.06%9.24%9.14%
Rest of the World Formulations Revenue
82.88B71.63B67.13B
Rest of the World Formulations Revenue Growth
15.72%6.70%11.09%
Total Formulations Revenue
542.46B497.42B455.71B
Total Formulations Revenue Growth
9.06%9.15%10.94%
Active Pharmaceutical Ingredients (API) Revenue
20.44B21.29B19.19B
Active Pharmaceutical Ingredients (API) Revenue Growth
-3.98%10.97%-2.72%
Others Segment Revenue
1.85B1.70B2.69B
Others Segment Revenue Growth
8.84%-36.74%18.02%
Other Operating Revenue
3.33B5.37B7.38B
Other Operating Revenue Growth
-37.98%-27.25%21.69%

Key Performance Indicators

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 Mar '19 Mar '18 Mar '17 Mar '16 Mar '15 Mar '14 Mar '13
Number of Medical Representatives
15.11K13.98K
Number of Medical Representatives Growth
8.04%10.18%
Sales per Medical Representative
11.20M10.60M
Sales per Medical Representative Growth
5.66%-0.94%
Updated Dec 31, 2025. Data Source: Fiscal.ai.